We can't find the internet
Attempting to reconnect
40713.1 IP-LS
40713.1 IP-LS
Résumé
Preclinical validation of PB002, a novel bacterial mix for the treatment of ulcerative colitis
Textes supplémentaires
Abstract
PharmaBiome is pioneering the development of next-generation microbiome therapies. To bridge the gap from proof of concept to the clinic we will validate the worldwide first co-cultivated microbiome product in relevant animal models of colitis as part of the preclinical studies.
Participants
Michael Scharl
Kontaktperson
michael.scharl@usz.ch
USZ Universitätsspital Zürich Division of Gastroenterology and He Michael Scharl Rämistrasse 100 8091 Zürich ZH CH
Florian Rosenthal
Wirtschaftspartner
f.rosenthal@pharmabiome.com
PharmaBiome AG CHE-190.589.234 Florian Rosenthal Wagistrasse 27 8952 Schlieren ZH CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2020-01-31
- Date de fin
- 2021-08-30
- Coûts totaux approuvés
- CHF 748761.00
- Section
- 60 Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T410 Pharmaceuticals and related technologies 100.0%